Clinical diagnosis of progressive supranuclear palsy: The movement disorder society criteria

Movement Disorders - Tập 32 Số 6 - Trang 853-864 - 2017
Günter U. Höglinger1,2, Gesine Respondek1,2, María Stamelou3, Carolin Kurz4, Keith A. Josephs5, Anthony E. Lang6, Brit Mollenhauer7, Ulrich Müller8, Christer Nilsson9, Jennifer L. Whitwell10, Thomas Arzberger11,4,2, Elisabet Englund12, Ellen Gelpí13, Armin Giese11, David J. Irwin14, Wassilios G. Meissner15,16,17, Alexander Pantelyat18, Alex Rajput19, Thilo van Eimeren20, Claire Troakes21, Angelo Antonini22, Kailash P. Bhatia23, Yvette Bordelon24, Yaroslau Compta25, Jean‐Christophe Corvol26,27,28, Carlo Colosimo29, Dennis W. Dickson30, Richard Dodel31, Leslie W. Ferguson19, Murray Grossman14, Jan Kassubek32, Florian Krismer33, Johannes Levin34,2, Stefan Lorenzl35,36,37, Huw R. Morris38, Peter J. Nestor39, Wolfgang H. Oertel40, Werner Poewe33, Gil D. Rabinovici41, James B. Rowe42, Daniela Berg43, Klaus Seppi33, Gregor K. Wenning33, Adam L. Boxer41, Lawrence I. Golbe44, Irene Litvan45
1Department of Neurology, Technische Universität München, Munich, Germany
2German Center for Neurodegenerative Diseases (DZNE), Munich, Germany
3Second Department of Neurology; Attikon University Hospital, University of Athens; Athens Greece
4Department of Psychiatry, Ludwig-Maximilians-Universität, Munich, Germany
5Department of Neurology, Mayo Clinic, Rochester, Minnesota, USA
6Morton and Gloria Shulman Movement Disorders Clinic and the Edmond J. Safra Program in Parkinson's Disease, Toronto Western Hospital, Toronto, Canada
7Paracelsus-Elena Klinik, Kassel, Germany, and University Medical Center Göttingen, Institute of Neuropathology; Göttingen Germany
8Institute of Human Genetics; Giessen Germany
9Department of Clinical Sciences, Division of Neurology, Lund University, Lund, Sweden
10Department of Radiology; Mayo Clinic; Rochester Minnesoya USA
11Center for Neuropathology and Prion Research, Ludwig-Maximilians-Universität, Munich, Germany
12Department of Clinical Sciences, Division of Oncology and Pathology, Lund University, Lund, Sweden
13Neurological Tissue Bank of the Biobank - Hospital Clínic de Barcelona; Universitat de Barcelona, IDIBAPS; Barcelona Spain
14Frontotemporal Degeneration Center; Department of Neurology, University of Pennsylvania; Philadelphia Pennsylvania USA
15CNRS, Institut des Maladies Neurodégénératives, UMR 5293, Bordeaux, France
16Service de Neurologie, Hôpital Pellegrin, CHU de Bordeaux; Bordeaux France
17Université de Bordeaux, Institut Des Maladies Neurodégénératives, UMR 5293, Bordeaux, France
18Department of Neurology; Johns Hopkins University; Baltimore, Maryland USA.
19Division of Neurology; Royal University Hospital, University of Saskatchewan; Saskatoon SK Canada
20Department of Neurology, Erasmus Medical Centre, Rotterdam, The Netherlands
21London Neurodegenerative Diseases Brain Bank; Institute of Psychiatry, Psychology and Neuroscience, Kings College London; London United Kingdom
22Parkinson and Movement Disorders Unit; IRCCS Hospital San Camillo, Venice, and Department of Neurosciences, Padova University; Padova Italy
23Sobell Department of Motor Neuroscience and Movement Disorders; UCL Institute of Neurology; Queen Square London United Kingdom
24Department of Neurology, University of California, Los Angeles, California, USA
25Parkinson's Disease & Movement Disorders Unit; Neurology Service, Hospital Clinic/IDIBAPS/University of Barcelona; Barcelona, Catalonia Spain
26AP-HP
27CNRS UMR_7225
28Sorbonne Universités, UPMC Univ Paris 06; and INSERM UMRS_1127, CIC_1422; and CNRS UMR_7225; and AP-HP; and ICM, Hôpital Pitié-Salpêtrière, Département des maladies du système nerveux; Paris France
29Department of Neurology; Santa Maria University Hospital of Terni; Terni Italy
30Mayo Clinic; Jacksonville Florida USA
31Department of Geriatric Medicine, University Hospital Essen, Essen, Germany
32Department of Neurology, University of Ulm, Ulm, Germany
33Department of Neurology, Medical University Innsbruck, Innsbruck, Austria
34Department of Neurology, Ludwig-Maximilians-Universität, Munich, Germany
35Department of Palliative Medicine, Munich University Hospital, LMU Munich, Munich, Germany
36Department of Palliative MedicineMunich University HospitalLMU Munich Munich Germany
37Institute of Nursing Science and Practice, Paracelsus Medical University, Salzburg, Austria
38Department of Clinical Neuroscience; UCL Institute of Neurology; London United Kingdom
39German Center for Neurodegenerative Diseases (DZNE), Magdeburg, Germany
40Department of Neurology, Philipps Universität, Marburg, Germany
41Memory and Aging Center; Department of Neurology, University of California; San Francisco California USA
42Department of Clinical Neurosciences, Cambridge University, Cambridge, United Kingdom
43Department of Pathology and Laboratory Medicine, Perelman School of Medicine University of Pennsylvania Philadelphia Pennsylvania USA
44Department of Neurology; Rutgers Robert Wood Johnson Medical School; New Brunswick New Jersey USA
45Department of Neurology; University of California; San Diego California USA

Tóm tắt

Từ khóa


Tài liệu tham khảo

Steele, 1964, Progressive supranuclear palsy. A heterogeneous degeneration involving the brain stem, basal ganglia and cerebellum with vertical gaze and pseudobulbar palsy, nuchal dystonia and dementia, Arch Neurol, 10, 333, 10.1001/archneur.1964.00460160003001

Litvan, 1996, Validity and reliability of the preliminary NINDS neuropathologic criteria for progressive supranuclear palsy and related disorders, J Neuropathol Exp Neurol, 55, 97, 10.1097/00005072-199601000-00010

Dickson, 1999, Neuropathologic differentiation of progressive supranuclear palsy and corticobasal degeneration, J Neurol, 246, II6, 10.1007/BF03161076

Kovacs, 2015, Neuropathology of tauopathies: principles and practice, Neuropathol Appl Neurobiol, 41, 3, 10.1111/nan.12208

Litvan, 1996, Clinical research criteria for the diagnosis of progressive supranuclear palsy (Steele-Richardson-Olszewski syndrome): report of the NINDS-SPSP international workshop, Neurology, 47, 1, 10.1212/WNL.47.1.1

Litvan, 1997, Which clinical features differentiate progressive supranuclear palsy (Steele-Richardson-Olszewski syndrome) from related disorders?. A clinicopathological study, Brain, 120, 65, 10.1093/brain/120.1.65

Lopez, 1999, Accuracy of four clinical diagnostic criteria for the diagnosis of neurodegenerative dementias, Neurology, 53, 1292, 10.1212/WNL.53.6.1292

Osaki, 2004, Accuracy of clinical diagnosis of progressive supranuclear palsy, Mov Disord, 19, 181, 10.1002/mds.10680

Williams, 2005, Characteristics of two distinct clinical phenotypes in pathologically proven progressive supranuclear palsy: Richardson's syndrome and PSP-parkinsonism, Brain, 128, 1247, 10.1093/brain/awh488

Respondek, 2014, The phenotypic spectrum of progressive supranuclear palsy: a retrospective multicenter study of 100 definite cases, Mov Disord, 29, 1758, 10.1002/mds.26054

Birdi, 2002, Progressive supranuclear palsy diagnosis and confounding features: report on 16 autopsied cases, Mov Disord, 17, 1255, 10.1002/mds.10211

Sakamoto, 2010, Clinical heterogeneity in progressive supranuclear palsy: problems of clinical diagnostic criteria of NINDS-SPSP in a retrospective study of seven Japanese autopsy cases, Neuropathology, 30, 24, 10.1111/j.1440-1789.2009.01032.x

Respondek, 2013, Accuracy of the National Institute for Neurological Disorders and Stroke/Society for Progressive Supranuclear Palsy and neuroprotection and natural history in Parkinson plus syndromes criteria for the diagnosis of progressive supranuclear palsy, Mov Disord, 28, 504, 10.1002/mds.25327

Litvan, 1996, Natural history of progressive supranuclear palsy (Steele-Richardson-Olszewski syndrome) and clinical predictors of survival: a clinicopathological study, J Neurol Neurosurg Psychiatry, 60, 615, 10.1136/jnnp.60.6.615

Kurz, 2016, An autopsy-confirmed case of progressive supranuclear palsy with predominant postural instability, Acta Neuropathol Commun, 4, 120, 10.1186/s40478-016-0391-7

Williams, 2010, What features improve the accuracy of the clinical diagnosis of progressive supranuclear palsy-parkinsonism (PSP-P)?, Mov Disord, 25, 357, 10.1002/mds.22977

Donker Kaat, 2007, Frontal presentation in progressive supranuclear palsy, Neurology, 69, 723, 10.1212/01.wnl.0000267643.24870.26

Han, 2010, Behavioral changes as the earliest clinical manifestation of progressive supranuclear palsy, J Clin Neurol, 6, 148, 10.3988/jcn.2010.6.3.148

Hassan, 2012, Autopsy-proven progressive supranuclear palsy presenting as behavioral variant frontotemporal dementia, Neurocase., 18, 478, 10.1080/13554794.2011.627345

Compta, 2007, Long lasting pure freezing of gait preceding progressive supranuclear palsy: a clinicopathological study, Mov Disord, 22, 1954, 10.1002/mds.21612

Facheris, 2008, Pure akinesia as initial presentation of PSP: a clinicopathological study, Parkinsonism Relat Disord, 14, 517, 10.1016/j.parkreldis.2007.11.004

Williams, 2007, Pure akinesia with gait freezing: a third clinical phenotype of progressive supranuclear palsy, Mov Disord, 22, 2235, 10.1002/mds.21698

Tsuboi, 2005, Increased tau burden in the cortices of progressive supranuclear palsy presenting with corticobasal syndrome, Mov Disord, 20, 982, 10.1002/mds.20478

Josephs, 2006, Clinicopathologic analysis of frontotemporal and corticobasal degenerations and PSP, Neurology, 66, 41, 10.1212/01.wnl.0000191307.69661.c3

Ling, 2014, Characteristics of progressive supranuclear palsy presenting with corticobasal syndrome: a cortical variant, Neuropathol Appl Neurobiol, 40, 149, 10.1111/nan.12037

Ling, 2010, Does corticobasal degeneration exist?. A clinicopathological re-evaluation, Brain, 133, 2045, 10.1093/brain/awq123

Josephs, 2006, Atypical progressive supranuclear palsy with corticospinal tract degeneration, J Neuropathol Exp Neurol, 65, 396, 10.1097/01.jnen.0000218446.38158.61

Nagao, 2012, Progressive supranuclear palsy presenting as primary lateral sclerosis but lacking parkinsonism, gaze palsy, aphasia, or dementia, J Neurol Sci, 323, 147, 10.1016/j.jns.2012.09.005

Kanazawa, 2009, Cerebellar involvement in progressive supranuclear palsy: a clinicopathological study, Mov Disord, 24, 1312, 10.1002/mds.22583

Iwasaki, 2013, An autopsied case of progressive supranuclear palsy presenting with cerebellar ataxia and severe cerebellar involvement, Neuropathology, 33, 561, 10.1111/neup.12012

Kanazawa, 2013, Early clinical features of patients with progressive supranuclear palsy with predominant cerebellar ataxia, Parkinsonism Relat Disord, 19, 1149, 10.1016/j.parkreldis.2013.07.019

Koga, 2016, Cerebellar ataxia in progressive supranuclear palsy: an autopsy study of PSP-C, Mov Disord, 31, 653, 10.1002/mds.26499

Boeve, 2003, Progressive nonfluent aphasia and subsequent aphasic dementia associated with atypical progressive supranuclear palsy pathology, Eur Neurol, 49, 72, 10.1159/000068502

Mochizuki, 2003, Progressive supranuclear palsy presenting with primary progressive aphasia-clinicopathological report of an autopsy case, Acta Neuropathol, 105, 610, 10.1007/s00401-003-0682-5

Josephs, 2006, Clinicopathological and imaging correlates of progressive aphasia and apraxia of speech, Brain, 129, 1385, 10.1093/brain/awl078

Josephs, 2008, Apraxia of speech and nonfluent aphasia: a new clinical marker for corticobasal degeneration and progressive supranuclear palsy, Curr Opin Neurol, 21, 688, 10.1097/WCO.0b013e3283168ddd

Scottish Intercollegiate Guidelines Network, 2008, SIGN 50. A Guideline Developer's Handbook

Respondek, Which ante-mortem clinical features predict progressive supranuclear palsy pathology?, Mov Disord

Whitwell, Radiological biomarkers for diagnosis in PSP: Where are we and where do we need to be?, Mov Disord

Hauw, 1994, Preliminary NINDS neuropathologic criteria for Steele-Richardson-Olszewski syndrome (progressive supranuclear palsy), Neurology, 44, 2015, 10.1212/WNL.44.11.2015

Höglinger, 2011, Identification of common variants influencing risk of the tauopathy progressive supranuclear palsy, Nat Genet, 43, 699, 10.1038/ng.859

Litvan, 2003, SIC Task Force appraisal of clinical diagnostic criteria for Parkinsonian disorders, Mov Disord, 18, 467, 10.1002/mds.10459

Boxer, Targeting tau therapeutics to PSP: support from new diagnostic criteria and biomarkers, Lancet Neurol

Kouri, 2015, Genome-wide association study identifies microtubule-associated protein tau (MAPT) and myelin-associated oligodendrocytic basic protein (MOBP) as shared genetic risk factors for corticobasal degeneration and progressive supranuclear palsy, Nat Commun, 6, 7247, 10.1038/ncomms8247

Lee, 2011, Clinicopathological correlations in corticobasal degeneration, Ann Neurol, 70, 327, 10.1002/ana.22424

Toledo, 2012, CSF biomarkers cutoffs: the importance of coincident neuropathological diseases, Acta Neuropathol, 124, 23, 10.1007/s00401-012-0983-7

Marquié, 2017, Pathologic correlations of [F-18]-AV-1451 imaging in non-Alzheimer tauopathies, Ann Neurol, 81, 117, 10.1002/ana.24844

Passamonti, 2017, [18F]AV-1451 positron emission tomography in Alzheimer's disease and progressive supranuclear palsy, Brain, pii, aww340, 10.1093/brain/aww340

Wood, 2013, Development and validation of pedigree classification criteria for frontotemporal lobar degeneration, JAMA Neurol, 70, 1411, 10.1001/jamaneurol.2013.3956

Otero-Millan, 2011, Distinctive features of saccadic intrusions and microsaccades in progressive supranuclear palsy, J Neurosci, 31, 4379, 10.1523/JNEUROSCI.2600-10.2011

Thông tin
Thông tin xuất bản

Movement Disorders

Tập 32 Số 6

853-864

Thông tin tác giả